Collegium Pharmaceutical (COLL) Cash & Current Investments (2014 - 2026)

Collegium Pharmaceutical's Cash & Current Investments history runs 13 years deep, the most recent figure standing at $288.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 45.87% year-over-year to $288.5 million in Q1 2026; TTM through Mar 2026 was $288.5 million, a 45.87% increase from a year earlier, with the FY2025 full-year figure at $251.1 million, up 54.27% from the prior year.
• Cash & Current Investments advanced to $288.5 million in Q1 2026 per COLL's latest filing, from $251.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $325.5 million in Q2 2023 and bottomed at $106.7 million in Q1 2022.
• The 5-year median for Cash & Current Investments is $251.1 million (2025), against an average of $222.4 million.
• Across the five-year window, Cash & Current Investments surged 165.21% in 2023 and tumbled 60.61% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $173.7 million in 2022, then soared by 78.8% to $310.5 million in 2023, then plunged by 47.59% to $162.8 million in 2024, then jumped by 54.27% to $251.1 million in 2025, then advanced by 14.89% to $288.5 million in 2026.
• Per Business Quant, the three latest COLL Cash & Current Investments figures stand at $288.5 million (Q1 2026), $251.1 million (Q4 2025), and $285.9 million (Q3 2025).